BioGaia ABBGLAF 100 Quick Ratio is 4.94 as of Mar. 2026, which is 10% below its 10-year median of 5.51. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 997 Drug Manufacturers companies, BioGaia AB ranks better than 88.77% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. BioGaia AB's quick ratio for the quarter that ended in Mar. 2026 was 4.94.
BioGaia AB has a quick ratio of 4.94. It generally indicates good short-term financial strength.
The historical rank and industry rank for BioGaia AB's Quick Ratio or its related term are showing as below:
BGLAF'
s Quick Ratio Range Over the Past 10 Years
Min: 2.69 Med: 5.51 Max: 16.75
Current: 4.94
During the past 13 years, BioGaia AB's highest Quick Ratio was 16.75. The lowest was 2.69. And the median was 5.51.
BGLAF's Quick Ratio is ranked better than 88.77% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs BGLAF: 4.94
BioGaia AB (OTCPK:BGLAF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
BioGaia AB Quick Ratio Related Terms
BioGaia AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
BioGaia AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Quick Ratio of 4.94 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioGaia AB and its competitors. This is 10% below median its historical median of 5.51. Over the past decade, BioGaia AB's Quick Ratio has ranged from 2.69 to 16.75. According to the industry distribution chart, BioGaia AB ranks #112 out of 997 companies in the Drug Manufacturers industry, placing it in the top 11.2%.
Is BioGaia AB's Quick Ratio too high?
BioGaia AB's current Quick Ratio of 4.94 is 10% below median its 10-year median of 5.51. Over the past 10 years, this metric has ranged from a low of 2.69 to a high of 16.75. The Drug Manufacturers industry median Quick Ratio is 1.45. BioGaia AB's value of 4.94 is 240.7% above this industry median. Based on the distribution chart, BioGaia AB ranks #112 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #112 out of 997 companies for Quick Ratio. This places BioGaia AB in the top 11% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. BioGaia AB's value of 4.94 is 240.7% above this benchmark. Historically, BioGaia AB's own Quick Ratio has ranged from 2.69 to 16.75 over the past decade. While the company's 10-year median is 5.51 vs. the industry median of 1.45, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Quick Ratio of 4.94 is 240.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Quick Ratio is 4.94, which is 10% below median its own 10-year median of 5.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current Quick Ratio of 4.94. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Quick Ratio is 4.94, which is 10% below median its 10-year median of 5.51 and 240.7% above the Drug Manufacturers industry median of 1.45. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Quick Ratio is 4.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
Quick Ratio: 4.94 (10% below median its 10-year median of 5.51)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 240.7% above the Drug Manufacturers median (#112 of 997)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
